Advertisement

Passive Immunization with Human Neutralizing Monoclonal Antibodies Against HIV-1 in Macaque Models: Experimental Approaches

  • Ruth M. Ruprecht
Protocol
Part of the Methods in Molecular Biology™ book series (MIMB, volume 525)

Abstract

After more than 20 years of intense research, a safe and effective vaccine against HIV-1/AIDS has not been developed. Passive immunization has been used as a tool to demonstrate the role of neutralizing antibodies in conferring protection against HIV-1 challenge in chimpanzees. Because these animals are endangered and studies are difficult to conduct with this species, chimeric viruses, termed simian-human immunodeficiency viruses (SHIVs), have been generated that encode the HIV-1 envelope gene in the backbone of the simian immunodeficiency virus (SIV). SHIVs replicate in several macaque species and can induce AIDS in these animals.

Passive immunization with human neutralizing monoclonal antibodies (nmAbs) against HIV-1 has protected rhesus macaques from SHIV infection and provided proof-of-concept of the protective effects of neutralizing antibodies. At the same time, human nmAbs can be evaluated for safety and efficacy in the SHIV/macaque model as therapeutic modalities in their own right for prevention, post-exposure prophylaxis, or possibly therapeutic use. Experimental details are provided for testing human nmAbs in infant rhesus monkeys, which allows testing without the need to generate large amounts of nmAbs.

Key words

Passive immunization neutralizing human monoclonal antibodies against HIV-1 SHIV protective epitopes non-human primate models 

Notes

Acknowledgment

The author would like to thank Susan Sharp for assistance in the preparation of this chapter. This work was supported by R37 AI034266 and PO1 AI048240.

References

  1. 1.
    Flynn, N.M., Forthal, D.N., Harro, C.D., Judson, F.N., Mayer, K.H., and Para, M.F. (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654–665.PubMedCrossRefGoogle Scholar
  2. 2.
    Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin M., van Griensven F., et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661–1671.PubMedCrossRefGoogle Scholar
  3. 3.
    Mc Cann, C.M., Song, R.J., and Ruprecht, R.M. (2005) Antibodies: can they protect against HIV infection? Curr. Drug Targets Infect. Disord. 5, 95–111.PubMedCrossRefGoogle Scholar
  4. 4.
    Kramer, V.G., Siddappa, N.B., and Ruprecht, R.M. (2007) Passive immunization as tool to identify protective HIV-1 Env epitopes. Curr. HIV Res. 5, 642–655.PubMedCrossRefGoogle Scholar
  5. 5.
    Ferrantelli, F., Rasmussen, R.A., Buckley, K.A., Li, P.L., Wang, T., Montefiori, D.C., et al. (2004) Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J. Infect. Dis. 189, 2167–2173.PubMedCrossRefGoogle Scholar
  6. 6.
    Hofmann-Lehmann, R., Swenerton, R.K., Liska, V., Leutenegger, C.M., Lutz, H., McClure, H.M., et al. (2000) Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Res. Hum. Retroviruses 16, 1247–1257.PubMedCrossRefGoogle Scholar
  7. 7.
    Baba, T.W., Liska, V., Hofmann-Lehmann, R., Vlasak, J., Xu, W., Ayehunie S., et al. (2000) Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6, 200–206.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Ruth M. Ruprecht
    • 1
  1. 1.Harvard Medical SchoolDana-Farber Cancer InstituteUSA

Personalised recommendations